beta-eudesmol + alpha-eudesmol in the AromaForge archive is not a single purified molecule but an analytical combined peak used where a GC report groups the two eudesmol isomers together. The strongest evidence here is identity and composition context: live source checks verify both parent constituents and confirm a public Siam wood COA that reports them as one shared sesquiterpene-alcohol fraction. Because the archived label is a co-reported analytical grouping rather than an isolated constituent, bioactivity and safety claims should stay conservative and defer to the underlying alpha- and beta-eudesmol records.
Chemical identity and composition
This record represents a combined reporting bucket rather than a unique registry species. The key public source located in this pass is a Siam wood GC certificate listing 'beta-Eudesmol + alpha-Eudesmol 4.24%' as one integrated peak, while NIST and PubChem identify beta-eudesmol and alpha-eudesmol separately as related eudesmane sesquiterpene alcohols with formula C15H26O.
Aroma and practical use
- Use the recorded woody, soft, terpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
There are no constituent-specific outcome findings in this report. No therapeutic benefit is inferred from its presence.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human safety paper was verified for the combined beta-eudesmol + alpha-eudesmol analytical label.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Practical interpretation should follow the parent oil context and, where needed, the separate alpha-eudesmol and beta-eudesmol constituent records rather than assume the combined peak has its own safety dossier.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no constituent-specific mechanism verified for the combined peak itself
Mechanistic literature exists for alpha- and beta-eudesmol individually, but not for the co-reported analytical grouping as a standalone entity.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No verified CAS number exists for the combined analytical label because it is a reporting bundle rather than a single molecule.
- No standalone study finding was located for the combined peak itself; the accessible literature treats alpha- and beta-eudesmol separately.
- A dedicated odor reference for the combined label was not verified, so descriptors remain low-confidence and inherited from the parent eudesmol profile context.
- 2026-07-13 verification pass: no individual IFRA Standard exists for eudesmol isomers (full-text keyword search of IFRA 51st Amendment for 'eudesmol', no match) and no Tisserand & Young Essential Oil Safety monograph or EU Cosmetics Regulation Annex III listing was located for either isomer or the combined peak. The prior dermal_limit_pct (20%) had no supporting citation and is corrected to null/unknown rather than presented as a sourced fact. As a combined analytical peak (not a single registry substance), this record is unlikely to ever have its own independent dermal-limit determination; any future safety data should attach to the individual alpha-eudesmol and beta-eudesmol records instead.
- No constituent-specific outcome findings are available in this report.
- No constituent-specific numeric dermal reference is available here.